Table 21:
Results Per Person of Long-Term (Testing, Treatment, and Care) Analysis
| Strategy | Average Total Costa (95% CrI) | Incremental Costa,b (95% CrI) | Average Effect (95% CrI) | Incremental Effect (95% CrI)b | ICERa,b | |||
|---|---|---|---|---|---|---|---|---|
| LY | QALY | LY | QALY | $/LY | $/QALY | |||
| Tissue biopsy alone | $78,952 (70,825-87,079) | – | 2.12 (2.06-2.19) | 1.10 (0.98-1.21) | – | – | – | – |
| Liquid biopsy alone | $81,227 (69,583-92,733) | $2,275 (-8,864-12,519) | 2.14 (2.02-2.25) | 1.12 (0.99-1.25) | 0.02 (-0.10-0.13) | 0.02 (-0.06-0.09) | $115,105 | $122,938 |
| Liquid biopsy as a triage test | $91,767 (83,511-100,065) | $10,539 (4,971-17,561) | 2.23 (2.14-2.31) | 1.18 (1.06-1.30) | 0.09 (0.03-0.16) | 0.05 (.02-0.11) | $117,046 | $175,502 |
Abbreviations: CrI, credible interval; ICER, incremental cost-effectiveness ratio; LY, life-years; QALY, quality-adjusted life-years.
a
Costs in 2018 Canadian dollars.
b
Numbers could appear incorrect because of rounding.